Bioventus, BCBS of Michigan partner in knee OA initiative — 3 things to know

Alan Condon -   Print  |
Listen

Bioventus is partnering with Blue Cross Blue Shield of Michigan to provide its knee osteoarthritis treatments to Medicare Advantage and Commercial patients, beginning Jan. 1, 2020.

Three things to know:

1. The arrangement includes Bioventus' Durolane, Gelsyn-3 and Supartz FX hyaluronic acid-based treatments for knee OA.

2. Durolane is a single-injection, Gelsyn-3 is a three-injection, and Supartz FX is a five-injection joint fluid treatment.

3. Earlier this year Bioventus signed a nationwide contract with UnitedHealthcare to make Durolane and Gelsyn-3 available to employer and individual commercial plans, starting Oct. 1.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers